Papilledema in 15 renally compromised patients treated with growth hormone
Papilledema in 15 renally compromised patients treated with growth hormone
复制标题
15 例接受生长激素治疗的肾功能不全患者出现视乳头水肿
DOI：
--
复制
发表时间：
1997
期刊：
影响因子：
--
通讯作者：
S. Malozowski
中科院分区：
文献类型：
--
作者：
E. Koller;B. Stadel;S. Malozowski
摘要：颅内高压伴视神经乳头水肿在肾脏病患者中已有报道，但文献调查显示其发生率较低。 我们报告了约1，670例肾脏疾病患者中的15例，这些患者接受生长激素治疗生长受损，随后出现颅内高压症状和/或体征。男女比例为6.5：1，中位年龄为12岁。症状或体征出现前生长激素治疗的中位持续时间为13周。除2例患者外，所有患者均出现症状。在已知已停止生长激素治疗的患者中，颅内高压的症状和体征减轻。这些患者中至少有4例在再次暴露于生长激素时复发。许多受影响的患者都有诱发条件，但生长激素似乎是诱发因素。对于正在接受生长激素治疗的肾脏疾病患者，可能需要进行前瞻性眼底镜评估。
Abstract. Intracranial hypertension with papilledema has been reported in renal patients, but a survey of the literature suggests that the incidence rate is low. We present reports of 15 of approximately 1,670 patients with renal disorders, who were treated with growth hormone for impaired growth and subsequently developed symptoms and/or signs of intracranial hypertension. The male:female ratio was 6.5:1, and the median age was 12 years. The median duration of growth hormone treatment before onset of symptoms or signs was 13 weeks. All but 2 patients were symptomatic. In the patients in whom growth hormone therapy is known to have been discontinued, the symptoms and signs of intracranial hypertension abated. At least 4 of these patients experienced a recurrence when re-exposed to growth hormone. Many of the affected patients presented with predisposing conditions, but growth hormone appears to have been the precipitating factor. Prospective funduscopic evaluation may be warranted in patients with renal disorders who are receiving growth hormone.